FIECON provides market access strategy and launch sequencing for a new haematology product in the Middle East by adapting models, assessing HTA landscapes, and guiding affiliate engagement to propose Saudi Arabia as an early launch market.
FIECON is consulting on the market access strategy and launch sequencing for a new haematology product approaching the market.
MA landscape assessment
We identify new HTA entities emerging via the Vision 2030 plan and map them to:
Evidence requirements
Decision processes
Key commercial steps
Model adaptation
We adapt a global model to the Saudi Arabian perspective by sourcing data and localizing the model with epidemiology, costs, and comparators. We reflect differences in treatment sequencing and positioning in the model update.
Additionally
We leverage the expertise of our affiliate network in Middle Eastern countries to capture all relevant insights.
Practical Agility
We are practically agile, operating with a lean structure that allows seamless teamwork and swift resource deployment, ensuring efficient project completion without unnecessary bureaucracy.
Re-framing the launch sequence for the product
We quantify the addressable market and potential reimbursed price, incorporating cross-HTA considerations like price referencing, and propose Saudi Arabia as an early launch market.
Affiliate engagement
We lead internal workshops with Middle East affiliates to help them effectively convey the evidentiary requirements and market opportunities in their respective countries.
FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”
Executive Director, Biotech
FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts. More info
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts.
